ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) reported a share repurchase on 10 June 2026, buying back 52,800 H shares on the Hong Kong Stock Exchange.

The repurchased shares were acquired at prices ranging from HKD 3.12 to HKD 3.27, representing a volume-weighted average cost of HKD 3.206 per share. Total consideration amounted to HKD 169,276 (approximately 0.17 million).

Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 0.0126 % to 419.74 million shares, while treasury shares rose to 734,600. The total number of issued shares, including treasury shares, remains unchanged at 420.48 million.

The buy-back formed part of a mandate approved on 28 May 2026 that allows the company to repurchase up to 43.15 million shares. Cumulative repurchases under this authority now stand at 734,600 shares, equivalent to 0.1702 % of the share count on the mandate’s approval date, leaving roughly 42.42 million shares available for future buy-backs.

In line with Hong Kong listing rules, IMMUNEONCO-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 10 July 2026. Management confirmed that the repurchase complied with all relevant regulatory and corporate requirements.